Title Page

Review of publicly available state reimbursement policies for removal and reinsertion of Long-Acting Reversible Contraception

Ekwutosi M. Okoroh ^{1, #a,¶}, Charlan D. Kroelinger ^{1,*} ¶, Olivia R. Sappenfield ^{2,¶}, Julia F. Howland ^{2,¶}, Lisa M. Romero ^{1,¶}, Keriann Uesugi ^{2,¶}, Shanna Cox ^{1,¶}

¹ Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

² Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois, United States of America

#aCurrent Address: River People Health Center, Indian Health Service, Scottsdale, Arizona, United States of America

*Corresponding author

Email: dwz8@cdc.gov (CDK)

¶These authors contributed equally to this work.

Short title: State policies on removal and reinsertion of Long-Acting Reversible Contraception

CReDit Taxonomy:

EMO conceptualized and developed the methodology for the study and led the original draft writing as well as the review and editing process.

CDK conceptualized and developed the methodology for the study, provided supervision, and led the original draft writing as well as the review and editing process.

ORS curated the data and participated in the investigation, led software development and formal analysis.

JFH curated the data and participated in the investigation, led software development and formal analysis.

LMR provided supervision and validation of data results.

KU led project administration and provided supervision, supported development of the methodology and resources, and supported conceptualization of the manuscript.

SC provided support in development of the methodology and provided review and editing of the manuscript.

Abstract

1

2

3

6

7

8

9

10

11

12

13

14

15

We examined reimbursement policies for the removal and reinsertion of long-acting reversible contraception (LARC). We conducted a standardized, web-based review of publicly available 4 state policies for language on reimbursement of LARC removal and reinsertion. We also 5 summarized policy language on barriers to reimbursement for LARC removal and reinsertion. Twenty-six (52%) of the 50 states had publicly available policies that addressed reimbursement for LARC removal. Of these, 14 (28%) included language on reimbursement for LARC reinsertion. Eleven states included language on barriers for reimbursement for removal and/or reinsertion: five state policies included language with other requirements for removal only, three policies included language with additional requirements for reinsertion only, and three included language with additional requirements for both. Three state policies specified no barriers be placed on reimbursement for removal and one specified no barriers be placed on reimbursement for reinsertion. Half of the states in the U.S. do not have publicly available

policies on reimbursement for the removal and reinsertion of LARC devices. Inclusion of

unrestricted access to these services is important for reproductive autonomy.

Introduction

16 17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

Reproductive autonomy includes the right to decide and control contraceptive use [1-2]. Longacting reversible contraception (LARC) methods (i.e. defined as intrauterine devices (IUD) and contraceptive implants) are safe, highly effective, and satisfactory options available to women who have been appropriately counseled [3]. Yet, multiple barriers to utilization have been identified [4–6] including hesitation from providers on 'early' LARC removal [7–9], delay in placement [10], and variations in available individual health coverage [11–12]. As of September 2010, the Affordable Care Act (ACA) requires many insurance plans to provide in-network coverage without cost sharing of certain clinical preventive services including all FDA-approved contraceptive methods [13]; however, additional requirements for reimbursement of services in individual state-level policies, exist. For instance, health plans or issuers of plans may use reasonable medical management techniques to control cost by imposing cost sharing when equivalent branded drugs are used [13]. Barriers to LARC removal and reinsertion access may also occur due to imposing prior authorization and step therapy, approval for medically necessary procedures only [9], or other non-medical reasons [11]. Therefore, it is important to understand how reimbursement policies for LARC devices, specifically for removal and reinsertion, affect health services delivery at the population level. This review summarizes language in state-level reimbursement policies on LARC removal and reinsertion, and language on reimbursement requirements.

Materials and methods

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

Study authors conducted a systematic, web-based review of publicly available state-level documents from October 2017 to May 2018. Detailed search terms, data abstraction process, and methodology are described elsewhere [14-15]. Briefly, reimbursement policies (e.g., Medicaid Bulletin, Family Planning Waiver, State Plan Amendment) authored by the state or an entity with authority to create billing policies, were categorized as 'State issued'. We used the term 'Health Plan', to categorize polices (e.g., Provider Manual and Insurance Manual) authored from a health plan with authority from the state to bill for services. When developing the definition of state-based reimbursement policies for LARC removal or reinsertion, study authors reviewed language in all documents that referred to or detailed reimbursement for LARC. If the word 'removal' or 'reinsertion' was included in the policy language or if the policy contained International Classification of Diseases codes (e.g., Z30.46, Z30.433) or Current Procedural Terminology (e.g., 11982, 11983, 58301) representing removal or reinsertion of a LARC device or Healthcare Common Procedure Coding System codes (e.g., J7296, J7297, J7300, J7307), [16] the state was categorized as having reimbursement policies for LARC removal or reinsertion. Likewise, a state was categorized as having reimbursement language for reinsertion if the language included words such as 'replacement' 'maintain' and/or 're-implanted' when describing LARC services or reimbursement policies. We categorized reimbursement requirements for removal or reinsertion into 'not specified' if policies did not specify reimbursement requirements for LARC removal or reinsertion, 'no requirement for provision of services' if the language prohibited limitations on removal or

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

5

Results

80

- Twenty-six (52%) of the 50 states had publicly available policies that addressed reimbursement
- 82 for LARC removal or reinsertion Table 1.
- 83 Table 1: Publicly Available Reimbursement Policies on LARC Removal Or Reinsertion By Policy

84 Type and Source for All States, 2017–2018. (N=50)

States	Policy Characteristics			
	Publicly Available Policy ^a	Policy	/ Types	Policy Source
		State	Health	
		Issued ^b	plan ^c	
Alabama	Yes	Yes	Yes	Medicaid Guidance & Health Plan Benefit Guide
Alaska	_	_	_	_
Arizona	_	_	_	_
Arkansas	Yes	Not available ^d	Yes	Health Plan Benefit Guide
California	Yes	Not available	Yes	Health Plan Benefit Guide
Colorado	_	_	_	_
Connecticut	_	_	_	_
Delaware	_	_	_	_
Florida	_	_	_	_
Georgia	_	_	_	_
Hawaii	Yes	Not available	Yes	Health Plan Benefit Guide
Idaho	Yes	Yes	Not available	Medicaid Guidance
Illinois	Yes	Yes	Yes	Statutory Provision & Health Plan Benefit Guide
Indiana	_	_	_	_
Iowa	_	_	_	_

Kansas	Yes	Yes	Yes	State Plan Amendment & Health Plan Benefit Guide
Kentucky	Yes	Not available	Yes	Health Plan Benefit Guide
Louisiana	_	_	_	_
Maine	Yes	Yes	Not available	Medicaid Guidance
Maryland	_	_	_	_
Massachusetts	Yes	Yes	Not available	Medicaid Guidance
Michigan	_	_	_	_
Minnesota	Yes	Not available	Yes	Health Plan Benefit Guide
Mississippi	_	_	_	_
Missouri	Yes	Yes	Not available	Medicaid Guidance
Montana	Yes	Yes	Not available	Medicaid Guidance
Nebraska	Yes	Yes	Not available	Medicaid Guidance & Title X
Nevada	Yes	Yes	Not available	Medicaid Guidance
New Hampshire	Yes	Yes	Not available	Medicaid Guidance
New Jersey	Yes	Not available	Yes	Health Plan Benefit Guide
New Mexico	Yes	Yes	Not available	Medicaid Guidance
New York	_	_	_	_
North Carolina	Yes	Yes	Yes	Statutory Provision & Health Plan Benefit Guide
North Dakota	Yes	Yes	Not available	Medicaid Guidance
Ohio	_		_	_
Oklahoma	Yes	Yes	Not available	State Plan Amendment
Oregon	_	_	_	_
Pennsylvania	_	_	_	_
Rhode Island	_		_	_
South Carolina	_	_	 	_

LARC, Long-acting reversible contraception

85

86

87

88 89

90 91

92

93 94

95

96

97

99

100

101

- ^c Health plan policy type represents reimbursement policies authored by a health plan, with authority from the state, to bill for services within the state.
- d 'Not available' represents policies that did not specify a statewide or a health plan policy type.
- While all 26 states included language in policies that addressed reimbursement for LARC
- removal, only 14 policies included language to address reinsertion Table 2.

^a The dashes in these columns represent states that **did not** have a publicly available policy.

^b State issued policy type represents reimbursement policies authored by the state or an entity with authority to create billing policies such as Medicaid, a Statute, or a State Plan Amendment.

Table 2: Summary of Reimbursement Policies and Requirements on LARC Removal or

Reinsertion Among States with Publicly Available Policies, 2017–2018 (N=26)

102

103

State with Publicly	Reimbursement Policy for LARC	Requirement for Reimbursing LARC	Reimbursement Policy for LARC	Requirement for Reimbursing
Available	Removal	Removal ^a	Reinsertion	LARC
Policies			L	Reinsertion
Alabama	Yes	Not specified	b	_
Arkansas	Yes	Not specified	_	_
California	Yes	Coverage-related	_	_
		requirements		
		Step-therapy related		
		requirements		
Hawaii	Yes	Time-related	_	_
		requirements		
Idaho	Yes	Diagnosis-related	_	_
		requirements		
Illinois	Yes	No restriction for	Yes	No restriction for
		provision of services		provision of
				services
Kansas	Yes	Not specified	_	_
Kentucky	Yes	Not specified	Yes	Time-related
				requirements
Maine	Yes	Not specified	_	_
Massachusetts	Yes	Not specified	Yes	Not specified
Minnesota	Yes	Not specified	Yes	Not specified
Missouri	Yes	Not specified	Yes	Not specified
Montana	Yes	Not specified	Yes	Not specified
Nebraska	Yes	Same-day related	Yes	Same-day
		requirements		related
				requirements
Nevada	Yes	Step-therapy related	Yes	Step-therapy
		requirements		related
				requirements
New	Yes	Not specified	Yes	Not specified
Hampshire				
New Jersey	Yes	Coverage-related	Yes	Coverage-related
		requirements		requirements
New Mexico	Yes	Not specified	<u> </u>	_
North Carolina	Yes	No restriction for	_	_
		provision of services		

North Dakota	Yes	Diagnosis-related requirements	_	_
Oklahoma	Yes	No restriction for provision of services	Yes	Time-related requirements
South Dakota	Yes	Time-related requirements	_	_
Utah	Yes	Not specified	_	_
Washington	Yes	Not specified	Yes	Not specified
West Virginia	Yes	Not specified	Yes	Time-related requirements
Wisconsin	Yes	Not specified	Yes	Not specified

LARC, Long-acting reversible contraception

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121 122

123

124125

126

127

128

129

130

^a Not specified represents policies that did not specify reimbursement requirements for LARC removal or reinsertion. Coverage-related requirements represent policy language that limits the reimbursement of LARC removal or reinsertion to preferred in-network providers or by other stipulations in the members' benefit coverage. Step-therapy related requirements represent policy language that allows for removal or reinsertion of LARC reimbursement only after a therapeutic equivalency device has been used. Time-related requirements represent policy language that limits the reimbursement of LARC removal or reinsertion to mandated periods of effectiveness (e.g., 3 years), or requires minimum time allotment prior to a device's removal or reinsertion (e.g., 6 months). Diagnosis-related requirements represent policy language that limits the reimbursement of LARC removal or reinsertion to when the removal or reinsertion was needed secondary to the presence of a medical condition (e.g., bleeding issues, infection) or when the patient was treated for an unrelated diagnosis or for a visit not coded as a family planning visit. No restriction for provision of services represents policies where the provided language specifically prohibits restrictions on removal or reinsertion services. Sameday related requirements represent policy language that limits reimbursement and no cost sharing, for the removal or reinsertion of LARC, to same day visits.

^b The dashes in these columns represent policies that **did not** include language on reinsertion or its reimbursement.

Three policies included language that specified no restrictions be placed on reimbursement for removal and one state specified no restrictions on reimbursement for reinsertion. The most common type of reimbursement requirement was time-related (n=5); the least common was same-day related requirements (n=1). Table 2.

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

We found that more than a quarter of states had policy language on reimbursement for LARC removal, while fewer addressed reimbursement for reinsertion. Only three states had policy language indicating no reimbursement requirement for provision of services. Most states with a publicly available reimbursement policy for LARC removal or reinsertion were Medicaid policies, with few states' Health Plans polices publicly available for review. The public availability of more Medicaid policies likely reflects the efforts undertaken by the Centers for Medicare and Medicaid Services (CMS)/Center for Medicaid and Children's Health Insurance Program Services (CMCS) who, in 2014, launched the Maternal and Infant Health Initiative with the primary goal of increasing access and use of effective contraceptives including LARC [17] though use among Medicaid recipients varies by state [17–18]. One potential reason for requirements for reimbursement could be concerns that 'early' removal would be costly [19–20]. However, LARC devices are cost neutral as early as three months post insertion, prior to full duration of effectiveness, when compared with short-acting reversible contraception options (i.e., patches, rings, oral contraceptive pills and injections) or no method use at all [21]. This finding of cost neutrality is still present even when the cost implications of removing the device before the end of its effective date is included [21]. Our findings of state-level variation in LARC removal and reinsertion reimbursement policies is consistent with existing literature demonstrating variation in LARC access policies. [9,11,14,15,

22]. Specific reimbursement practices may present barriers for LARC removal or reinsertion. For

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170171

172

173

174

175

women in states with policies that include reimbursement requirements, such as diagnosis and time-related requirements, preferences for LARC maybe impacted if women lack assurance that removal will be covered [9,23]. Moreover, access to LARC removal or reinsertion without restrictions is vitally important, particularly for populations who have experienced restraint of reproductive autonomy (e.g., American Indian/Alaskan Native people, Black people, people with disabilities, people experiencing poverty and people who are incarcerated or detained) [24-30]. Recognizing these concerns, national clinical organizations encourage patient-centered counseling based on individual patient contraceptive preferences, needs, and values, thus ensuring that patient values guide all clinical decisions [31]. Similarly, the American College of Obstetricians and Gynecologists recommends a reproductive justice framework be employed during contraceptive counseling which entails shared decision-making with the patient and provision of information on the benefits and risks of all contraceptive methods with the avoidance of potential coercion [32]. Recently, a multidisciplinary group of experts developed a Reproductive and Sexual Health Equity framework; a key principle is the concept of honoring bodily autonomy, emphasizing ongoing difficulties women have accessing LARC removal [33]. Several limitations exist in interpreting our findings. First, we did not contact all states to verify their reimbursement policies on removal or reinsertion of LARC. Second, we only included publicly available policies, potentially missing any new, non-publicly available or unpublished policies. Third, while our reviewed focused on reimbursement policies and its effect on LARC

access, numerous other barriers such as lack of provider knowledge [34], blocked time for

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

provider training [35], credentialing gaps [36], and myths and misinformation from patients [32] may contribute to the ability of women to access LARC removal and/or reinsertion. Fourth, since the data collection timeframe, some state policies may have been reviewed or amended, potentially affecting our categorization of policy language. However, amendment of state policies may require multiple annual policy cycles depending on whether the policy is a law, regulation, standard, or protocol [17]. Given that reimbursement policies can influence service delivery [37], review of language may identify administrative, financial, or medical barriers to reimbursement for LARC removal or reinsertion [9,30,38]. For example, states could consider including reimbursement language that allows providers to bill per-service rather than per-visit, allowing insertion, removal, or reinsertion of a LARC during a single clinical encounter [39], if desired by the woman. Lastly, standardizing training of family medicine [35] or primary care residents [36] on insertion and removal with expanded reimbursement could increases timely access to LARCs. LARC removal and reinsertion are important aspects of contraception access. Reimbursement requirements may restrict contraceptive access. Removal of barriers to these services supports both the ability of providers to offer comprehensive contraceptive services, and patient reproductive autonomy.

Acknowledgements

None.

References

- Gomez AM, Fuentes L, Allina A. Women or LARC first? Reproductive autonomy and the promotion of long-acting reversible contraceptive methods. Perspect Sex Reprod Health. 2014 Sep. doi: 10.1363/46e1614.
- Upadhyay UD, Dworkin SL, Weitz TA, Foster DG. Development and validation of a reproductive autonomy scale. Stud Fam Plann. 2014 Mar. doi: 10.1111/j.1728-4465.2014.00374.x.
- 3. Trussell J. Contraceptive failure in the United States. Contraception. 2011; 83(5): 397–404.
- Hopkins B. Barriers to Health Care Providers' Provision of Long-Acting Reversible Contraception to Adolescent and Nulliparous Young Women. Nurs Womens Health. 2017; 21(2): 122–128.
- Baron MM, Potter B, Schrager S. A Review of Long-Acting Reversible Contraception Methods and Barriers to Their Use. WMJ: official publication of the State Medical Society of Wisconsin. 2018; 117(4): 156–159.
- Holden EC, Lai E, Morelli SS, Alderson D, Schulkin J, Castleberry NM, McGovern PG.
 Ongoing barriers to immediate postpartum long-acting reversible contraception: a physician survey. *Contracept Reprod.* 2018 Nov 08. doi: 10.1186/s40834-018-0078-5.

- 7. Amico JR, Bennett AH, Karasz A, Gold M. "I wish they could hold on a little longer": physicians' experiences with requests for early IUD removal. Contraception. 2017; 96(2): 106–110.
- 8. Manzer JL, Bell AV. The limitations of patient-centered care: The case of early long-acting reversible contraception (LARC) removal. Soc Sci Med. 2022 Jan. doi: 10.1016/j.socscimed.2021.114632.
- Strasser J, Borkowski L, Couillard M, Allina A, Wood SF. Access to Removal of Long-acting Reversible Contraceptive Methods Is an Essential Component of High-Quality Contraceptive Care. Womens Health Issues. 2017; 27(3): 253–255.
- 10. Runyan A, Welch RA, Kramer KJ, Cortez S, Roberts LJ, Asamoah C, et al. Long-Acting Reversible Contraception: Placement, Continuation, and Removal Rates at an Inner-City Academic Medical Center Clinic. J Clin Med. 2021 Apr 28. doi: 10.3390/jcm10091918.
- 11. Armstrong E, Gandal-Powers M, Levin S, Kimber Kelinson A, Luchowski AT, Thompson K.
 Intrauterine devices and implants: A guide to reimbursement. ACOG, NFPRHA, NHeLP,
 NWLC, UCSF.2015. Available from https://larcprogram.ucsf.edu/
- 12. Ela EJ, Broussard K, Hansen K, Burke KL, Thaxton L, Potter JE. Satisfaction, Resignation, and Dissatisfaction with Long-Acting Reversible Contraception among Low-Income Postpartum Texans. Womens Health Issues. 2022 Jul-Aug. doi: 10.1016/j.whi.2022.02.006.
- 13. Department of Labor/Health and Human Services/and Treasury. FAQs About Affordable Care Act Implementation (Part XXVI). 2015; Available from: Affordable Care Act Implementation FAQs - Set 12 | CMS.

- 14. Kroelinger CD, Okoroh EM, Uesugi K, Romero L, Sappenfield O R, Howland JF, et al.

 Immediate Postpartum Long-Acting Reversible Contraception: Review of Insertion and

 Device Reimbursement Policies. Womens Health Issues. 2021; 31(6): 523–531.
- 15. Romero L, Sappenfield OR, Uesugi K, Howland JF, Kroelinger CD, Okoroh EM, et al.
 Review of Publicly Available State Policies for Long-Acting Reversible Contraception
 Device Reimbursement. J Womens Health (Larchmt). 2022 Jan 17. doi:
 10.1089/jwh.2021.0361.
- 16. The American College of Obstetricians and Gynecologists. Coding for the Contraceptive Implant and IUDs. 2021; Available from: https://www.acog.org/-/media/project/acog/acogorg/files/pdfs/publications/larc-coding-guide.pdf.
- 17. Centers of Medicare and Medicaid Services. CMCS informational bulletin: state Medicaid payment approaches to improve access to long-acting reversible contraception. 2016; Available from https://www.medicaid.gov/sites/default/files/Federal-Policy-Guidance/Downloads/CIB040816.pdf
- 18. Rodriguez MI, Meath THA, Watson K, Daly A, Tracy K, McConnell KJ. Geographic Variation In Effective Contraceptive Use Among Medicaid Recipients In 2018. Health Aff (Millwood). 2023 Apr. doi: 10.1377/hlthaff.2022.00992.
- 19. Chiou CF, Trussell J, Reyes E, Knight K, Wallace J, Udani J, et al. Economic analysis of contraceptives for women. Contraception. 2003; 68(1):3-10.

- 20. Eisenberg D, McNicholas C, Peipert JF. Cost as a barrier to long-acting reversible contraceptive (LARC) use in adolescents. J Adolesc Health. 2013 Apr. doi: 10.1016/j.jadohealth.2013.01.012.
- 21. Trussell J, Hassan F, Lowin J, Law A, Filonenko A. Achieving cost-neutrality with long-acting reversible contraceptive methods. Contraception 2015; 91(1): 49–56.
- 22. Walls J, Gifford K, Ranji U, Salganicoff A, Gomez I. Medicaid coverage of family planning benefits: Results from a state survey. 2022; Available from: https://www.kff.org/womens-health-policy/report/medicaid-coverage-of-family-planning-benefits-findings-from-a-2021-state-survey/
- 23. Sobel L, Salganicoff A, Kurani N. Coverage of contraceptive services: A review of health insurance plans in five states. 2015. Available from:
 http://kff.org/reportsection/coverage-of-contraceptive-services-introduction/
- 24. Lawrence J. The Indian Health Service and the sterilization of Native American women.

 American Indian quarterly. 2000; 24(3): 400–419.
- 25. Roberts D. Killing the Black Body: Race, Reproduction, and the Meaning of Liberty, New York: Vintage Book; 1997.
- 26. Stern AM. Sterilized in the name of public health: race, immigration, and reproductive control in modern California. Am J Public Health. 2005; 95(7): 1128–1138.
- 27. Paltrow LM, Flavin J. Arrests of and forced interventions on pregnant women in the United States, 1973-2005: implications for women's legal status and public health. J Health Polit Policy Law. 2013; 38(2): 299–343.

- 28. Ohlheiser A. California Prisons Were Illegally Sterilizing Female Inmates. Atlantic. 2013

 Jul 7 [Cited 2024 March 11]. Available from:

 https://www.theatlantic.com/national/archive/2013/07/california-prisons-were-illegally-sterilizing-female-inmates/313591/
- 29. Gold RB. Guarding Against Coercion While Ensuring Access: A Delicate Balance.

 Guttmacher Policy Review. 2014; 17:8-14.
- 30. Levandowski BA, Green T, Liu L, Betstadt S, Thevenet-Morrison K, Harrington A. Results of Immediate Postpartum Long Acting Reversible Contraception Provision After Expanded Reimbursement Policy Implementation at an Academic Medical Institution.

 Matern Child Health J. 2023 Nov. doi: 10.1007/s10995-023-03738-w.
- 31. Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. National Academies Press (US); 2001
- 32. ACOG Committee Opinion No. 735: Adolescents and Long-Acting Reversible

 Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2018; 131(5): e130–e139.
- 33. Dehlendorf C, Akers AY, Borrero S, Callegari LS, Cadena D, Gomez AM, et al. Evolving the Preconception Health Framework: A Call for Reproductive and Sexual Health Equity.

 Obstet Gynecol. 2021; 137(2): 234–239.
- 34. Luchowski AT, Anderson BL, Power ML, Raglan GB, Espey E, Schulkin J. Obstetriciangynecologists and contraception: practice and opinions about the use of IUDs in

- nulliparous women, adolescents and other patient populations. Contraception. 2014 89(6): 572–577.
- 35. Callen EF, Na'Allah R, Lewis A, Kerns J, Hester CM. Block Scheduling for LARC in a Family Medicine Residency Program. Fam Med. 2023 Dec 20. doi: 10.22454/FamMed.2023.253918. Epub ahead of print. PMID: 38241742.
- 36. Holaday LW, Gover M, Iyer SV, DeLuca JP, Stella J, Gold M, et al. Effectiveness of training primary care internal medicine residents in etonogestrel implants and impact on their future practice: A cross-sectional study. Contraception. 2022 Nov. doi: 10.1016/j.contraception.2022.07.013.
- 37. Vela VX, Patton EW, Sanghavi D, Wood SF, Shin P, Rosenbaum S. Rethinking Medicaid Coverage and Payment Policy to Promote High Value Care: The Case of Long-Acting Reversible Contraception. Womens Health Issues. 2018; 28(2): 137–143.
- 38. Centers for Disease Control Prevention. The 6/18 initiative: Prevent unintended pregnancy. 2016; Available from:

https://www.cdc.gov/sixeighteen/pregnancy/index.htm

39. Orris A, Mauser G, Bachrach D, Grady A. A toolkit for states enhancing access to family planning services in Medicaid: ManattHealth. 2019; Available from: Arnold-Ventures Family-Planning-Toolkit FINAL.PDF (manatt.com)